FEELM
14.9.2023 13:17:29 CEST | Business Wire | Press release
At the renowned InterTabac 2023 exhibition, held from September 14-16, FEELM, the world leading closed system solution provider, unveiled its latest innovation OS Vape in partnership with OS. It is the first time FEELM has co-exhibited with its local partner.
Since its inception in 1978, InterTabac has been recognized as the world's premier trade fair for tobacco products and smoking accessories. This distinguished gathering provides a platform for industry professionals to interact with top-tier representatives spanning retail, manufacturing, and service sectors. As testament to the evolving landscape of the tobacco world, in recent years, the spotlight has increasingly shone on brands from the rapidly expanding European vaping area.
FEELM’s First Co-Exhibition
OS, recognized as a dominant force in Germany's shisha product market, ventured into the disposable vape industry. Seizing this opportunity, this co-exhibition represents a significant breakthrough for FEELM, emphasizing its commitment to innovative strategies in delivering comprehensive solutions to its clients.
A representative from the FEELM booth shared that collaborating with clients for exhibitions is a new strategy aimed at bolstering the client's brand presence in local markets. The representative further revealed that FEELM intends to continue this co-exhibition format at major global exhibitions, joining forces with clients from various regions in a collective march towards a global presence.
OS Vape with More Puff Counts and Premium Taste Consistency
Germany, celebrated for its beers bursting with hop aroma and refreshingly pure taste, is a nation where lively spirits indulge in robust drinking. Stepping into this vibrant culture, OS Vape introduced a disposable vaping solution that delivers an elevated puff count, cost-efficiency, and unmatched vapor consistency, promising German consumers a rich vaping experience reminiscent of their cherished beers.
Elevated by the FEELM Max ceramic coil technology, OS Vape has achieved a groundbreaking 800+ puffs. This represents an impressive 30%+ enhancement in puff count compared to other common disposable products, establishing a new standard under TPD compliance. Thus, OS Vape has distinguished itself as the pioneer in Germany to set this benchmark.
Beyond puff count, OS Vape offers an exceptional vapor and taste consistency of over 95%. These groundbreaking advancements have undoubtedly propelled the vaping industry to new zeniths. Additionally, the signature transparent e-liquid tank not only alleviates e-liquid concerns but also adds a touch of aesthetic sophistication.
Authoritative Institution-Certified 800-Puff Report
Given the debut of the 800+ puff disposable product in Germany, there was keen interest in the technical solution behind it. At the Dortmund expo, many attendees procured verification reports from one of the most authoritative testing institute, Inter Scientific, revealing that the FEELM Max solution can consistently deliver between 880-920 puffs.
During the exhibition, numerous esteemed brands, such as Aroma King, have also embraced the 800+ puff benchmark, joining hands with FEELM, collaboratively setting new puff standards in the TPD market, and heralding a new era of vaping innovations and heightened consumer expectations.
About FEELM
As a flagship tech brand under SMOORE, FEELM is the world's leading provider of closed vape system solutions. Harnessing the power of Ceramic Coil Heating Technology and authentic Flavor Reproduction Technology, FEELM merges innovation and electronics to deliver the ultimate sensation and a premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 11 technology research centers worldwide and products are available in more than 80 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914578369/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom